Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (symbol: COYA) is a clinical-stage biotechnology company dedicated to pioneering therapies that regulate the function of regulatory T cells (Tregs). The company focuses on developing novel and proprietary medicinal products aimed at modulating Tregs to treat a range of debilitating diseases, including neurodegenerative, autoimmune, and metabolic disorders.
With a strong emphasis on scientific innovation, Coya Therapeutics is engaged in multi-modality Treg therapies designed to address unmet medical needs in these critical areas. By harnessing the power of Tregs, the company aims to restore immune balance and bring new hope to patients suffering from conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.
In recent developments, Coya Therapeutics has made significant strides in its research and development programs, advancing its pipeline of therapeutic candidates. The company is currently engaged in multiple clinical trials to evaluate the safety and efficacy of its Treg-targeted treatments. These efforts are supported by a robust financial condition, strategic partnerships, and collaborations with leading research institutions and healthcare organizations.
Coya Therapeutics' commitment to scientific excellence and patient well-being positions it as a key player in the biotechnology sector. Investors and stakeholders can look forward to updates on clinical trial progress, new product developments, and potential market launches that underscore the company's growth trajectory and impact on the healthcare landscape.
Stay tuned to Coya Therapeutics' news releases and financial reports for the latest information on the company's achievements and future directions.
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on enhancing regulatory T cell (Treg) function, has announced its participation in the Chardan 8th Annual Genetic Medicines Conference. The event will take place on September 30 – October 1, 2024, at the Westin Grand Central in New York City.
CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will engage in a fireside chat on Tuesday, October 1, 2024, at 2:00pm ET. The discussion will be moderated by Keay Nakae, Senior Research Analyst at Chardan Capital Markets. Both executives will also be available for one-on-one meetings throughout the conference.
Coya Therapeutics (NASDAQ: COYA) announces promising results for COYA 302, a subcutaneously administered anti-inflammatory biologic, in a preclinical Parkinson's disease (PD) mouse model. The study shows that COYA 302 significantly reduces neuroinflammation in key brain regions affected by PD, including:
- Decreased microglial activation in the nigrostriatal pathway
- Reduced astrocyte numbers and activation (astrogliosis)
These findings suggest that COYA 302 can directly modulate brain inflammation when administered peripherally, potentially offering a new therapeutic approach for PD and other neurodegenerative diseases like Alzheimer's and Frontotemporal Dementia. The company plans to present or publish these results in a peer-reviewed setting.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on enhancing regulatory T cell function, announces CEO Howard Berman's participation in two upcoming healthcare conferences. On September 26, 2024, Dr. Berman will join a panel discussion at Munsch Hardt's 3rd Annual Texas Health Care Transactions Conference in Houston. On October 28, 2024, Dr. Berman and Dr. Stanley Appel will present data on COYA 302 at the inaugural Alzheimer's Drug Discovery Foundation (ADDF) Summit in Madrid, Spain.
The company will also present results from a Gates Foundation and Alzheimer's Association funded study on low-dose interleukin-2 in Alzheimer's patients at the Clinical Trials on Alzheimer's Disease conference. In May 2024, Coya received a $5 million strategic equity investment from ADDF to support COYA 302's development for Frontotemporal Dementia treatment.
Coya Therapeutics (NASDAQ: COYA) has announced a leadership transition, with Arun Swaminathan Ph.D. promoted to Chief Executive Officer effective November 1, 2024. Dr. Howard Berman, the company's founder, will transition to Executive Chair of the Board. Dr. Swaminathan, who joined Coya as Chief Business Officer in April 2023, has been instrumental in executing several significant commercial transactions, including Coya's recent $700 million licensing deal with Dr. Reddy's Laboratories.
The company is preparing for the release of Alzheimer's data at the CTAD24 conference on October 29, 2024, and continues to progress COYA 302 in ALS. Coya believes Dr. Swaminathan's experience will be valuable in advancing COYA 302 in related programs such as Frontotemporal Dementia, Parkinson's Disease, and other immune-mediated diseases.
Coya Therapeutics (Nasdaq: COYA) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Received a $5 million investment from the Alzheimer's Drug Discovery Foundation for COYA 302 development in Frontotemporal Dementia.
2. Obtained $3.85 million from Dr. Reddy's Laboratories for COYA 302's Phase 2 ALS trial.
3. Published promising Phase 1 results for CTLA4-Ig and IL-2 combination in ALS patients.
4. Expanded research collaboration with Houston Methodist Research Institute.
5. Filed new U.S. patents for COYA 301 in combination with GLP-1 receptor agonists.
6. Q2 2024 financials: $36.6 million cash on hand, R&D expenses of $4.6 million, and net loss of $2.9 million.
Coya Therapeutics (NASDAQ: COYA) has announced that results from a double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease will be presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid on October 29, 2024. The study, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and Alzheimer's Association, evaluated 38 patients over 30 weeks. This presentation replaces the previously announced topline data release planned for Summer 2024. A prior open-label study showed that low-dose IL-2 was well-tolerated and resulted in significant improvements in cognitive function and regulatory T cell (Treg) function and numbers in AD patients.
Coya Therapeutics (NASDAQ: COYA) has filed for intellectual property protection for the combination of COYA 301 (low-dose interleukin-2) and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs). This combination aims to enhance regulatory T cell function and may offer a multi-pathway targeted approach for treating inflammatory diseases, including neurodegenerative, autoimmune, and metabolic conditions.
The company believes this proprietary combination could lead to value-creating business development partnerships and expand the GLP-1 market beyond diabetes and obesity. Data suggests the combination may have additive and/or synergistic anti-inflammatory effects on multiple cell types. Coya is investigating these combinations to potentially bring forward an optimized novel therapeutic approach for several diseases.
Coya Therapeutics has expanded its research collaboration with the Houston Methodist Research Institute (HMRI) to advance the development of regenerative T cell (Treg) exosome technology. This initiative is funded by the Johnson Center for Cellular Therapeutics and aims to progress towards a first-in-human clinical study. The collaboration will also focus on validating clinical biomarkers for neurodegenerative diseases and exploring drug combinations, particularly COYA 301 (low dose interleukin-2) and COYA 302 (LD IL-2 + CTLA4-Ig). These efforts could offer new therapeutic avenues for conditions like ALS, Alzheimer's, and Parkinson's Disease.
Coya Therapeutics has published a study in Frontiers in Neurology on an ALS treatment using a combination of CTLA4-Ig and Low Dose Interleukin-2. The treatment showed promising results in halting disease progression over 24 weeks and reducing inflammation and oxidative stress. Four participants were administered the treatment, which was well-tolerated with no serious adverse events. The study revealed an improvement or stability in ALSFRS-R scores and significant enhancement in Regulatory T cell function. The company plans to file an IND application with the FDA for a larger, randomized controlled trial.
Coya Therapeutics (NASDAQ: COYA) announced the acceptance of a peer-reviewed manuscript in Frontiers in Neurology. The study, titled 'A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,' highlights the halting of ALS progression at six months. The therapy also showed reduced inflammation and oxidative stress, and enhanced Regulatory T cell (Treg) function. This data was previously presented at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference. Dr. Fred Grossman, Coya's Chief Medical Officer, sees this as significant validation for their approach.
FAQ
What is the current stock price of Coya Therapeutics (COYA)?
What is the market cap of Coya Therapeutics (COYA)?
What does Coya Therapeutics, Inc. specialize in?
What are regulatory T cells (Tregs)?
What types of diseases is Coya Therapeutics targeting?
What are the recent achievements of Coya Therapeutics?
How is Coya Therapeutics funded?
What is the significance of Treg therapies?
Are there any ongoing clinical trials by Coya Therapeutics?
Who are Coya Therapeutics' partners?
What can investors expect from Coya Therapeutics?
How can I stay updated on Coya Therapeutics' news?
